Diagnostic procedures during the course of Parkinson's Disease

Basal Ganglia

Volumn 4, Issue 1, 2014, Pages 15-18

  Kassubek, Jan ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Biomarker; Diagnosis; Neurodegeneration; Neuroimaging; Parkinson's Disease

Indexed keywords

ALPHA SYNUCLEIN; APOMORPHINE; DJ 1 PROTEIN; LEVODOPA;

CEREBROSPINAL FLUID EXAMINATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE MARKER; ECHOENCEPHALOGRAPHY; HUMAN; HYPOSMIA; LABORATORY DIAGNOSIS; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASOMNIA; PARKINSON DISEASE; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOM; VOXEL BASED MORPHOMETRY;

EID: 84901687024     PISSN: 22105336     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.baga.2014.02.001     Document Type: Review

References (40)

1. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181-184.
2. Chaudhuri K.R., Schapira A.H. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009, 8:464-474.
3. Braak H., Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol 2009, 201:1-119.
4. Halliday G., Lees A., Stern M. Milestones in Parkinson's disease - clinical and pathologic features. Mov Disord 2011, 26:1015-1021.
5. Hawkes C.H., Del Tredici K., Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord 2010, 16:79-84.
6. Caslake R., Moore J.N., Gordon J.C., Harris C.E., Counsell C. Changes in diagnosis with follow-up in an incident cohort of patients with parkinsonism. J Neurol Neurosurg Psychiatry 2008, 79:1202-1207.
7. Winkler J., Ehret R., Büttner T., Dillmann U., Fogel W., Sabolek M., et al. Parkinson's disease risk score: moving to a premotor diagnosis. J Neurol 2011, 258:S311-S315.
8. McGhee D.J., Royle P.L., Thompson P.A., Wright D.E., Zajicek J.P., Counsell C.E. A systematic review of biomarkers for disease progression in Parkinson's disease. BMC Neurol 2013, 13:35.
9. Clarke C.E., Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 2000, 69:590-594.
10. Doty R.L. Olfactory dysfunction in Parkinson disease. Nat Rev Neurol 2012, 8:329-339.
11. Doty R.L. Olfaction in Parkinson's disease and related disorders. Neurobiol Dis 2012, 46:527-552.
12. Morley J.F., Duda J.E. Olfaction as a biomarker in Parkinson's disease. Biomark Med 2010, 4:661-670.
13. Iranzo A., Tolosa E., Gelpi E., Molinuevo J.L., Valldeoriola F., Serradell M., et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 2013, 12:443-453.
14. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003, 2:229-237.
15. Litvan I., Goldman J.G., Tröster A.I., Schmand B.A., Weintraub D., Petersen R.C., et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012, 27:349-356.
16. Brown R.G., Lacomblez L., Landwehrmeyer B.G., Bak T., Uttner I., Dubois B., et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010, 133:2382-2393.
17. Del Tredici K., Jost W.H. Gastrointestinal dysfunction in idiopathic Parkinson's disease. Nervenarzt 2012, 83:1282-1291.
18. Kassubek J., Danek A., Del Tredici-Braak K., Greenlee M.W., Pinkhardt E.H. The eye as a window to the pathophysiology in Parkinson's syndromes. Nervenarzt 2013, 84:909-917.
19. Sauerbier A., Chaudhuri K.R. Parkinson's disease and vision. Basal Ganglia 2013, 3:159-163.
20. Pinkhardt E.H., Kassubek J. Ocular motor abnormalities in Parkinsonian syndromes. Parkinsonism Relat Disord 2011, 17:223-230.
21. Schneider M., Müller H.P., Lauda F., Tumani H., Ludolph A.C., Kassubek J., et al. Retinal single-layer analysis in Parkinsonian syndromes: an optical coherence tomography study. J Neural Transm 2014, 121:41-47.
22. Parnetti L., Castrioto A., Chiasserini D., Persichetti E., Tambasco N., El-Agnaf O., et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 2013, 9(3):131-140.
23. Mollenhauer B. Quantification of α-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson's disease. Parkinsonism Relat Disord 2014, 20:S76-S79.
24. Devic I., Hwang H., Edgar J.S., Izutsu K., Presland R., Pan C., et al. Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 2011, 134:e178.
25. Wünsch G., Weishaupt A., Volkmann J., Steigerwald F. Diagnostic value of saliva biomarkers in PD?. Basal Ganglia 2013, 3:46.
26. Vlaar A.M., van Kroonenburgh M.J., Kessels A.G., Weber W.E. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 2007, 7:27.
27. Vogt T., Kramer K., Gartenschlaeger M., Schreckenberger M. Estimation of further disease progression of Parkinson's disease by dopamin transporter scan vs clinical rating. Parkinsonism Relat Disord 2011, 17:459-463.
28. Shtilbans A., Henchcliffe C. Biomarkers in Parkinson's disease: an update. Curr Opin Neurol 2012, 25:460-465.
29. Tang C.C., Poston K.L., Eckert T., Feigin A., Frucht S., Gudesblatt M., et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010, 9:149-158.
30. Stoessl A.J. Functional imaging studies of non-motoric manifestations of Parkinson's disease. Parkinsonism Relat Disord 2009, 15:S13-S16.
31. Berg D. Transcranial ultrasound as a risk marker for Parkinson's disease. Mov Disord 2009, 24:S677-S683.
32. Seppi K., Poewe W. Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clin N Am 2010, 20:29-55.
33. Rizzo G., Martinelli P., Manners D., Scaglione C., Tonon C., Cortelli P., et al. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease. Brain 2008, 131:2690-2700.
34. Scherfler C., Schocke M.F., Seppi K., Esterhammer R., Brenneis C., Jaschke W., et al. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. Brain 2006, 129:538-542.
35. Zhan W., Kang G.A., Glass G.A., Zhang Y., Shirley C., Millin R., et al. Regional alterations of brain microstructure in Parkinson's disease using diffusion tensor imaging. Mov Disord 2012, 27:90-97.
36. Mahlknecht P., Hotter A., Hussl A., Esterhammer R., Schocke M., Seppi K. Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease. Neurodegener Dis 2010, 7:300-318.
37. Kassubek J., Pinkhardt E.H., Dietmaier A., Ludolph A.C., Landwehrmeyer G.B., Huppertz H.J. Fully automated atlas-based MR imaging volumetry in Huntington disease, compared with manual volumetry. AJNR Am J Neuroradiol 2011, 32:1328-1332.
38. Duncan G.W., Firbank M.J., O'Brien J.T., Burn D.J. Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease. Mov Disord 2013, 28:425-438.
39. Berg D., Lang A.E., Postuma R.B., Maetzler W., Deuschl G., Gasser T., et al. Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol 2013, 12:514-524.
40. Parkinson Progression Marker Initiative The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011, 95:629-635.